NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
NAMS moved a median of -0.15% 30 minutes after news, and -0.27% by the close. How NAMS actually reacts to news — the realized, point-in-time move the market made, measured across 378 labeled events over the last three years with zero look-ahead.
NAMS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 377 |
| 30-min | -0.15% | 48% | 377 |
| 60-min | 0.00% | 48% | 378 |
| to close | -0.27% | 47% | 378 |
| Middle 50% of NAMS reactions | -1.21% to +1.31% |
|---|---|
| Median reaction (30-min) | -0.15% |
| Measured reactions | 378 |
Half of all NewAmsterdam Pharma Company N.V. - Ordinary Shares news events land between -1.21% and +1.31% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NAMS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 42 | -0.52% | 29% | -1.65% |
| Rating reiterations | 52 | +0.26% | 56% | -0.34% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how NAMS ranks against every other measured name →
That’s how NAMS usually reacts — get an email when it moves on news →Email me when NAMS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NAMS's baseline. Nothing else.
Recent NAMS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.74% | -0.17% | |
| NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease | Press release | GlobeNewswire | +0.81% | +1.23% | |
| Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) | Press release | PR Newswire | -0.75% | +0.00% | |
| NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) | Press release | GlobeNewswire | -1.96% | -1.61% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.16% | -0.97% | |
| NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September | Press release | GlobeNewswire | +1.03% | +1.75% | |
| NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 | Press release | GlobeNewswire | +0.18% | +0.66% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.94% | -0.32% | |
| NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results | Press release | GlobeNewswire | -2.43% | +0.33% | |
| NewAmsterdam Pharma to Host Investor Day on August 5, 2026 | Press release | GlobeNewswire | +1.22% | -1.20% | |
| NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) | Press release | GlobeNewswire | -1.07% | -3.98% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.55% | +0.14% | |
| NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 | Press release | GlobeNewswire | +0.19% | +2.45% | |
| NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions | Press release | GlobeNewswire | -0.87% | +1.32% | |
| NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June | Press release | GlobeNewswire | -2.02% | -2.85% | |
| NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May | Press release | GlobeNewswire | +6.33% | +5.24% | |
| NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results | Press release | GlobeNewswire | -2.85% | +5.48% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.98% | +5.51% | |
| NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -0.84% | -2.83% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.03% | +3.77% | |
| NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session | Press release | GlobeNewswire | -1.79% | +1.63% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.74% | +3.64% | |
| Form 8-K NewAmsterdam Pharma Co For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -5.36% | |
| NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March | Press release | GlobeNewswire | +1.22% | -3.10% | |
| Form 10-K NewAmsterdam Pharma Co For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.99% | +1.33% | |
| Form 8-K NewAmsterdam Pharma Co For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +0.99% | +1.33% | |
| Form S-8 NewAmsterdam Pharma Co | SEC filing · Form S-8 | SEC EDGAR | +0.99% | +1.33% | |
| NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.99% | +1.33% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.60% | +1.83% | |
| NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit | Press release | GlobeNewswire | +1.13% | -1.17% | |
| Form 8-K NewAmsterdam Pharma Co For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.35% | -6.12% | |
| NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities | Press release | GlobeNewswire | +0.35% | -6.12% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.72% | +0.18% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.60% | -0.34% | |
| NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December | Press release | GlobeNewswire | -1.07% | +1.81% | |
| NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +9.97% | +10.99% | |
| Form 10-Q NewAmsterdam Pharma Co For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.00% | +6.17% | |
| Form 8-K NewAmsterdam Pharma Co For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +2.00% | +6.17% | |
| NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results | Press release | GlobeNewswire | +2.00% | +6.17% | |
| NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November | Press release | GlobeNewswire | +0.00% | +8.16% | |
| Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation | Press release | PR Newswire | -0.77% | +2.49% | |
| NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum | Press release | GlobeNewswire | +1.43% | +0.91% | |
| Form 8-K NewAmsterdam Pharma Co For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +2.50% | |
| Menarini Group's Obicetrapib and Obicetrapib/Ezetimibe Marketing Authorisation Applications Accepted for Review by the European Medicines Agency (EMA) for the Treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) | Press release | PR Newswire | +0.02% | +2.50% | |
| NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September | Press release | GlobeNewswire | -1.34% | -2.91% | |
| Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site | Press release | PR Newswire | -0.91% | +1.33% | |
| Form 8-K NewAmsterdam Pharma Co For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | +1.11% | |
| NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib | Press release | GlobeNewswire | -1.39% | +1.11% | |
| Form 8-K NewAmsterdam Pharma Co For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | +1.11% | |
| Form 10-Q NewAmsterdam Pharma Co For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.72% | +9.10% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NAMS section they belong to.
Where else NAMS is measured.
NAMS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NewAmsterdam Pharma Company N.V. - Ordinary Shares's median reaction calculated?
Every labeled NAMS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 378 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 48% of NAMS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NAMS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.